月份: 2026 年 3 月

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 3月26日，中國生物製藥有限公司公佈 2025 全年業績。年內實現營業收入318.3 億元（人民幣，下同），按年增長 10.3%；經調整Non-HKFRS歸母淨利潤45.4 億元，按年增長 31.4%，連續四個財報期維持雙位數增長，整體表現明顯優於行業平均水平。集團最核心亮點在於創新產品商業化持續放量。2025 年創新產品收入達152.2 億元，按年大增 26.2%，規模處於行業前列，高增速反映創新轉型成效顯著，亦為業績提供可持續支撐。2023‑2025 年三年間，集團累計獲批創新產品 16 款，其中國藥 1 類創新藥達 7 款，成果轉化效率領先行業，成為帶動業績增長的關鍵動力。年內集團再添 4 款創新藥獲國家藥監局（NMPA）批准上市，包括針對 HER2 肺癌、CDK2/4/6 抑制劑、重組七因子及獲 FDA 批準的鎮痛新藥等具突破性產品。核心品種安羅替尼再增 3 項一線適應症，總數擴至 10 項，進一步鞏固抗血管生成藥物領先地位。在腫瘤、肝病 / 心血管代謝、呼吸 / 自免、外科 / 鎮痛四大核心領域，公司已建立完整產品矩陣，支撐長期穩健增長。董事會主席謝其潤表示，連續四期雙位數增長驗證集團在創新研發、BD 合作及併購整合的長期佈局成效。2026 年是集團全面國際化的新起點，年初重磅對外授權項目成為重要里程碑，為創新管線打開全球估值空間。研發方面，集團維持高強度投入，2025 年研發開支達58.7 億元，按年增長逾 15%，佔收入比重 18.4%，雙雙創歷史新高。目前已搭建小分子、ADC、siRNA、蛋白降解劑等多個核心技術平台，於上海、北京、廣州等地設立研發中心，研發團隊超 2900 人，推進臨床項目超 130 個。透過 AI 技術賦能研發全流程，PCC 發現時間提速超 50%，臨床篩選週期縮短約 30%，研發質效顯著提升。首席執行長謝承潤指出，集團在鞏固本土優勢之餘，堅定推進國際化與數碼化戰略，多項重磅創新資產已具備全球競爭力。2026 年開局表現強勢：1 月以 12 億元收購 siRNA 技術平台赫吉亞；2 月 FIC 新藥羅伐昔替尼獲批，並將全球權益授權予賽諾菲，交易潛在總金額超 15 億美元，開啟國際化第二增長曲線。展望未來三年（2026‑2028），集團創新管線將進入密集收穫期，預計逾 20 款創新藥或新適應症有望上市，涵蓋多個 FIC/BIC 潛力品種。於腫瘤、呼吸、肝病代謝、外科鎮痛領域均有重磅品種推進，包括 CLDN18.2 ADC、雙抗、PDE3/4 抑制劑、pan‑PPAR 激動劑等，管線梯次清晰、儲備充足。整體而言，中國生物製藥已由仿製驅動成功轉向創新驅動，憑藉高研發投入、高效商業化與國際化佈局，進入高質量增長階段。隨著創新產品持續放量、管線逐步兌現，集團長期增長動能充足，在港股藥板塊中具備突出配置價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial Highlights (Audited)(HKD Thousand)Year ended31 December20252024Revenue170,011271,372Gross Profit53,382104,720Profit Attributable to Owners of the Company13,68833,440Basic Earnings per Share (HK cents)0.972.37HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2025 (“the Year”).In 2025, due to the impact of macroeconomy as well as weak demand in wine consumer market in the PRC, the Group’s sales of medium to high-end products significantly declined, resulting in a 37% year-on-year decrease in revenue to HK$170.0 million. In addition, due to the decline in sales revenue and gross margin, as well as an increase in loss allowances for trade receivables owing to extended repayment from certain distributors, the profit attributable to owners of the Company decreased by 59% year-on-year to approximately HK$13.7 million, although such decrease in profit was already partly offset by a net gain on compensatory surrender recognised during the year. Earnings per share of the Company was HK0.97 cents per Share.With strengthened marketing effort for dry white in coastal region and the launch of new white wine and sparkling wine products, sales of white wine products served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 39% and 54% of the revenue respectively for the year (2024: approximately 41% and 56% respectively). The gross margin of red wine products and white wine products in 2025 were 25% and 35% respectively (2024: 36% and 41% respectively). The overall gross profit margin decreased to 31% in 2025 (2024: 39%), mainly due to change in product mix with more products with lower prices and margin in response to market dynamics and needs during the year.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new gift set product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of “tea and wine fusion,” has captured market attention with its unique craftsmanship. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Ningxia Winery won industry praise for their unique flavor and exquisite craftsmanship. In the second half of the year, the Group also introduced new products “Hi” tea-flavoured wine series in response to the market need, which are very suitable for ready-to-drink scenarios among young consumers.In addition to enriching the product matrix, the Group has been closely cooperating with distributors, pressing ahead with its marketing campaign, accelerating the innovation of consumption scenarios, and enhancing and strengthening the wine cultural experience. The Group held its national tour tasting and business events, new products launch ceremonies at various exhibitions and wine fairs, as well as promotion activities for the 20th anniversary of listing in Hong Kong, during which the Group actively promoted its latest product mix that covered all product lines.During the year, two joint venture companies approved by the Group were established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine and trading of sauce-flavour baijiu products nationwide in the PRC respectively. For the yellow wine project, installation and testing of production equipment of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu is expected to be completed in the second half of 2026. Upon completion of the project, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry. The project expansion aims to effectively implement Dynasty’s strategic plan, further improving the industrial layout, expanding category tracks, tapping into industry potential, creating new performance growth points, and realising Dynasty Group’s transformation into a full category, full industry-chain enterprise. For the sauce-flavour baijiu segment, Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in the core-market in Tianjin and Shanghai and will be further strategically promoted to other regions in 2026. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo  for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote, Kuai and TikTok. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. The Group jointly develops exclusive products with leading e-commerce platforms, and promote AI livestreaming models in various channels to increase brand exposure and livestreaming sales, adopts big data analysis to accurately understand consumer demand, and injects strong momentum into the continued expansion of market scale. To establish an online brand matrix, the Group selected and authorised new online distributors during the year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.During the year, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series – Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world. Dynasty has won the Silver Medal in the Sparkling Wine/China category, the Silver Medal in the Dry Wine/China category, and the Bronze Medal in the Medium/China category for its Dynasty Tianyang Winery Jasmine Sparkling Wine, Dynasty Inherit Series – Dry Red Wine, and Dynasty Inherit Series – Semi Dry White Wine, respectively, at the 2025 Cathay Global Wine & Spirits Awards Asia (“GWSAA”) (formerly known as the Cathay Hong Kong International Wine & Spirit Competition (“HKIWSC”)). This marks the 15th consecutive year that Dynasty products have won awards at the event, demonstrating industry-wide recognition of Dynasty’s exceptional winemaking skill and quality. In addition, “Dynasty Pinyue VSOP brandy” also won the Gold Medal in the brandy category of 2025 China Fine Wine Challenge.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2026, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to uphold quality, seize the development trend of low-alcohol and younger consumer markets, and proactively develop new marketing prospects through innovation in products categories and consumption scenarios.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China.For media enquiries:Strategic Financial Relations (China) LimitedMs. Anita Cheung Tel: 2864 4827Ms. Gianna Ye    Tel: 2864 4837Ms. Hazel Ye     Tel: 2864 4893Ms. Chloe Lyu    Tel: 2864 4835Email: sprg-dynasty@sprg.com.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

財務摘要 (經審核)（港幣千元）截至十二月三十一日止年度 2025年2024年收入170,011271,372毛利53,382104,720本公司所有者應佔溢利13,68833,440每股基本盈利 (港仙)0.972.37香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 中國優質葡萄酒生產商王朝酒業集團有限公司(「王朝」或「集團」)(股份代號：00828)今日公佈截至2025年12月31日止（「年內」）經審核之全年業績。2025年，受宏觀經濟和中國葡萄酒消費市場需求疲弱的情況影響，集團中高檔產品銷售下滑，收入較去年同比減少37%至1.70億港元。另外由於銷售收入及毛利率下降，以及部分經銷商延遲還款導致應收賬款虧損撥備增加，本公司所有者應佔溢利較去年同比減少59%至13.7百萬港元，儘管溢利減少部分已被年內確認的補償交出淨收益所抵消。集團每股基本盈利為每股0.97港仙。隨著集團在沿海地區加大對乾白葡萄酒市場的推廣力度，並推出新款白葡萄酒及起泡酒產品，白葡萄酒產品的銷售已成為集團的主要收入來源。紅葡萄酒及白葡萄酒產品的銷售分別佔集團於年內收入的約39%及54%（2024年：分別為約41%及56%）。於2025年，紅葡萄酒產品及白葡萄酒產品的毛利率分別為25%及35%（2024年：分別為36%及41%）。整體毛利率減少至31%（2024年：39%），主要由於年內因應市場動態及需求調整產品組合併降低銷售價格及利潤率。集團積極求新，聚焦「5+4+N產品戰略」，其中「N」代表集團推出N項需求定制，不斷開拓創新產品，以滿足中國不同類型消費群體的多元化需求。年內，集團推出禮盒新品－王朝乙巳蛇年生肖紀念乾紅葡萄酒，與中國生肖文化相融合，引領「國潮風」，以年輕化的視覺語言呈現生肖文化，吸引潛在消費者。此外，基於其現有的優質產品，集團繼續推出新產品並推進產品升級。集團於2025年3月在第112 屆全國糖酒商品交易會上推出天陽茶酒系列、王朝百馥VSOP白蘭地等新品，以進一步完善其產品矩陣，為消費者提供多元的消費選擇。該系列茶香葡萄酒突破傳統葡萄酒的局限，以「茶酒融合」為核心理念，憑藉獨特的釀造工藝迅速獲得市場目光。在全國糖酒商品交易會期間，集團亦舉辦品酒會，而王朝寧夏酒莊的新品憑藉獨特的風味和精湛的釀造工藝，贏得業界的好評。下半年，集團亦因應市場需求，推出全新產品「嗨」茶風味酒系列，非常適合年輕消費者的即飲場景。除了豐富產品矩陣外，集團與經銷商緊密合作，積極推進市場推廣活動，加速創新消費場景，提升及強化葡萄酒文化體驗。集團於各類展覽及葡萄酒博覽會舉行期間，舉辦了全國巡迴品鑒會及招商活動、新品發佈會以及香港上市20週年推廣活動，期間集團大力推廣其全系列的最新產品組合。年內，集團批准設立的兩間合資公司於2025年2月成立，分別從事黃酒及陳皮酒生產及銷售，以及於全國範圍內買賣醬香型白酒產品。對於黃酒項目，江蘇的一座儲罐容量為3,000 噸黃酒及特種黃酒－陳皮酒的生產設備及安裝及測試預期將於2026年下半年完成建設。於項目完成後，集團將能夠生產特種黃酒－東台陳皮酒，讓集團可有效擴展產品品類，把握中國黃酒行業的發展機遇，進一步優化集團產業佈局，拓展品類版圖，實現王朝向全品類、全產業鏈企業的轉型。對於醬香型白酒領域，王朝醬香型白酒產品，即「漢」、「唐」、「宋」、「明」，已於天津及上海核心市場新推出，並將於2026年進一步戰略推廣至其他地區。醬香型白酒產品滿足不同消費習慣的客戶群體的需求，並為集團業務作出貢獻。未來，醬香型白酒產業的持續發展及擴張及客戶群體水平的提升，必將有效推動王朝葡萄酒及相關產品銷售規模的增長，從而提升行業影響力及品牌知名度。電商銷售方面，集團的電商團隊於傳統電商平台全面運營在線商店銷售產品，例如京東商城、天貓商城及拼多多，以及通過興趣電商平台（包括小紅書app、快手app 及抖音app）全面創新品牌、品類、業務體系、流程和模式。集團繼續為改善網上銷售渠道及時投入資源，優化在線商店界面，以把握中國客戶消費行為的變化，與頭部電商平台共同開發專屬產品，並通過多種渠道推廣人工智能直播模型以提升品牌曝光度及直播銷售額，採用大數據分析以精準洞察消費者需求，為市場規模持續擴大注入強勁動力。為建立線上品牌矩陣，集團於年內甄選及開放新店線上經銷商授權。集團相信線上平台不僅是集團與消費者之間的企業對客戶交易平台，亦是品牌新增的市場推廣及宣傳渠道，從而提升集團的整體業務潛力。年內，集團在大型葡萄酒品鑒大賽中屢獲殊榮。在多個獎項中，「王朝錦邑桶藏12年XO白蘭地」榮獲2025年國際葡萄酒與烈酒大賽（「IWSC」）中的銀獎。該比賽被視為葡萄酒和烈酒質量的國際評價標準。王朝百馥VSOP白蘭地、金王朝馬瑟蘭乾紅葡萄酒以及天陽茶酒系列亦於中國酒業協會舉辦的「二零二四年青酌獎」各類別評選中獲獎。「王朝夢園白葡萄酒」亦以其卓越的酒質榮獲2025年春季FIWA法國國際葡萄酒大獎賽中國區金獎。此外，「王朝傳承系列－乾紅葡萄酒」於同一比賽中榮獲金獎。該等葡萄酒因其酒香優雅、酒體順滑和口感圓潤從眾多參賽作品中脫穎而出，並在比賽中獲得獎項，向國家及世界展示了王朝葡萄酒的魅力和實力。王朝旗下產品「王朝天陽酒莊茉莉葡萄起泡酒」、「王朝傳承乾紅葡萄酒」以及「王朝傳承半乾白葡萄酒」分別於2025年度國泰環球葡萄酒及烈酒大獎亞洲（「GWSAA」）（前稱國泰航空香港國際美酒品評大獎（「HKIWSC」））榮獲中國產區品評組別下氣泡酒、乾型酒銀獎殊榮，以及中國產區品評組別下半乾型酒銅獎殊榮。這是王朝產品連續15年於該獎項中獲得佳績，標誌著王朝在葡萄酒釀造技藝與卓越品質方面再次獲得業界的高度認可。此外，「王朝品悅VSOP白蘭地」在2025年中國優質葡萄酒挑戰賽中榮獲白蘭地類別金獎。王朝主席萬守朋先生總結︰「展望2026年，本集團將繼續以市場及消費者需求為導向，重塑消費情景，提升產品質量。同時，本集團將繼續創新市場營銷策略，激發品牌活力，進一步擴大王朝產品的市場佔有率，加強王朝品牌作為國產葡萄酒代表的形象，並為中國葡萄酒行業樹立標桿，將王朝美酒風尚帶給更多的中國消費者。本集團將繼續秉持品質至上，把握低酒度飲品及年輕消費者市場的發展趨勢，並通過產品品類及消費場景的創新，積極開拓新的市場前景。」關於王朝酒業集團有限公司王朝酒業集團有限公司於2005年1月26日在香港聯合交易所有限公司主板上市，股份代號00828。成立於1980年，王朝為中國優質葡萄酒生產商，主要生產及銷售「王朝」商標的葡萄酒產品，是中國第一家中外合資的釀酒企業，主要股東包括天津食品集團有限公司及法國葡萄酒巨頭人頭馬集團。集團產銷葡萄酒産品系列超過100種，及引入進口葡萄酒產品，為國內各消費層提供高質素及物超所值的葡萄酒。新聞垂詢：縱橫財經公關顧問(中國)有限公司張麗雲小姐 電話：2864 4827葉甘霖小姐 電話：2864 4837葉婉鈴小姐 電話：2864 4893呂昕純小姐 電話：2864 4835電郵：sprg-dynasty@sprg.com.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the first two months of 2026, the total value of exports of goods amounted to $928.3 billion, marking an increase of 29.6% from the same period of last year.Hong Kong Trade Development Council’s Director of Research Bruce Pang said, over the past few months, Hong Kong’s external trade has continued to exhibit clear growth momentum. Although global geopolitical conditions remain tense, underlying demand from the Chinese Mainland and major overseas markets has remained resilient. We maintain a positive outlook, yet remain cautious in regard to Hong Kong’s trade performance.”HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, N.Y., Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - OpenClawd AI today released a security-focused platform update that adds automated skill vetting, verified installer sourcing, and runtime sandboxing to its managed OpenClaw hosting service. The update responds to two converging threats targeting users of the open-source AI agent formerly known as Clawdbot and Moltbot: a large-scale malware campaign inside the official OpenClaw skill marketplace, and a parallel wave of counterfeit installation packages being promoted through search engine results.The numbers are bad enough on their own. Together, they describe a supply chain that is actively hostile to casual users.One in Eight OpenClaw Skills Is Confirmed MaliciousIndependent security researchers recently completed an audit of the ClawHub skill marketplace — the primary distribution channel for third-party OpenClaw plugins. Out of 2,857 published skills, 341 were confirmed as malicious. That is approximately 12% of the entire marketplace.The findings include:Keyloggers and credential stealers deployed through skills that appear to offer legitimate productivity featuresSilent data exfiltration — one widely-downloaded skill was found to instruct the OpenClaw agent to execute curl commands that sent user data to an external server without any notification or consent promptPrompt injection payloads embedded in skill descriptions, designed to override the agent’s safety guidelines and force execution of unauthorized commandsPlaintext credential exposure — a separate audit found that over 280 additional skills were leaking API keys, tokens, and passwords in their source codeA major cybersecurity firm tested a specific ClawHub skill and published the results: nine security findings, including two critical and five high-severity issues. The skill functioned as what the researchers called “functionally malware.” The most widely-downloaded malicious skill on ClawHub was a cryptocurrency stealer.Fake OpenClaw Installers Are Being Promoted by Search EnginesThe marketplace problem is only half the story. A cybersecurity research team discovered that threat actors have published counterfeit OpenClaw installation packages on open-source code repositories. These fake installers mimic the legitimate OpenClaw setup process but instead deliver a malware packer that disables firewall protections and routes network traffic through compromised systems.The attack chain is straightforward: a user searches for “install OpenClaw” or “Clawdbot download.” An AI-powered search engine returns a result linking to the malicious repository. The user follows the instructions. The malware deploys silently.The researcher who discovered the campaign noted that the person who first reported the threat was a technical professional. “If a fellow IT pro is susceptible to this threat,” he said, “then anyone could be.”“There are now two ways to get compromised before you even run your first OpenClaw command,” said Danny Wilson, spokesperson for OpenClawd. “You can install a fake version of the software, or you can install the real version and then add a skill that steals your data. We built this update so that neither path exists on our platform.”What OpenClawd Ships TodayThis update targets both the supply chain and the runtime:Verified installer sourcing — all OpenClawd instances are provisioned from cryptographically signed OpenClaw releases, pulled directly from the official repository. No third-party install paths. No search engine intermediaries.Skill vetting pipeline — third-party skills go through automated static analysis and behavioral testing before activation. Skills flagged for network exfiltration, prompt injection patterns, or credential exposure are blocked by default.Runtime sandboxing — each skill executes in an isolated environment with explicit permission boundaries. A skill that requests network access to an unexpected endpoint triggers a review before execution.Credential isolation — API keys and tokens are stored in encrypted vaults and never exposed in plaintext to skill code or agent logsAutomatic CVE patching — hosted instances track the latest stable OpenClaw release (currently v2026.3.x), with all known vulnerabilities patched before deploymentOpenClawd does not operate its own skill marketplace. Skills available on hosted instances are drawn from the official ClawHub repository after passing the vetting pipeline described above.OpenClawd is not affiliated with the OpenClaw open-source foundation, OpenAI, Peter Steinberger, or any third-party security research firm cited in this release. It is an independent platform built on the open-source Clawdbot codebase. The open-source project remains free at github.com/openclaw/openclaw.Pricing starts with a free tier. Paid plans include dedicated compute, priority security patching, and uptime monitoring. Deploy a secure OpenClaw instance at https://openclawd.ai.Contact:Email: support@openclawd.ai  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Development Highlights- During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year increase of 26.2%. In addition, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou, and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalable formulations, transdermal patches and other fields.- As at 31 December 2025, the Group had a total of 39 innovative oncology drug candidates, 10 innovative liver/cardiometabolic drug candidates, 14 innovative respiratory/autoimmune drug candidates, and 6 innovative surgery/analgesia drug candidates in the process of clinical trial application or above. Of these, 1 innovative oncology drug candidate and 2 innovative surgery/analgesia drug candidates are in the marketing application stage; and 13 innovative oncology drug candidates, 1 innovative liver/cardiometabolic drug candidate, 5 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. Also, 9 innovative oncology drug candidates, 6 liver/cardiometabolic drug candidates, 5 innovative respiratory/autoimmune drug candidates, and 2 innovative surgery/analgesia drug candidates are in Phase II clinical trials. In addition, the Group had a total of 16 innovative oncology drug candidates, 3 innovative liver/cardiometabolic drug candidates, 4 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate in Phase I clinical trials.- Focus V(R) (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor that has been approved for 10 indications. It has several new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2025, the Group obtained marketing approval for 7 national category 1 innovative oncology drugs, namely, Saitanxin(R) (Culmerciclib capsule), Hernexeos(R) (Zongertinib table), Yilishu(R) (Efbemalenograstim alfa Injection), Andewei(R) (Benmelstobart Injection), Anboni(R) (Unecritinib Fumarate Capsules), Anluoqing(R) (Envonalkib Citrate Capsules), and Anfangning(R) (Garsorasib Tablets). It also obtained marketing approval for 4 oncology biosimilars, including Anbeisi(R) (Bevacizumab Injection), Delituo(R) (Rituximab Injection), Saituo(R) (Trastuzumab for Injection), and Paletan(R) (Pertuzumab Injection). The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.- Tianqing Ganmei(R) (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for 3 indications. During the Year, the Group made efforts to strengthen academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.- TQC3721 (PDE3/4 inhibitor) is a dual PDE3/4 inhibitor currently undergoing Phase III clinical trials in China for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The Group is developing a variety of dosage forms of TQC3721: a suspension for inhalation is in Phase III clinical trials, and an inhaled dry powder formulation is in Phase II clinical trials. The different dosage forms are expected to further enhance patient compliance.- Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of highpotential regions, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2025 (the “Year”).During the Year, the Group's revenue increased by approximately 10.3% to approximately RMB31.83 billion. Profit attributable to owners of the parent from continuing operations (as reported) was approximately RMB2.34 billion, a year-on-year increase of approximately 22.0%. Basic earnings per share attributable to owners of the parent from the continuing operations were approximately RMB13.02 cents, an increase of approximately 24.0% over last year. Underlying profit attributable to owners of the parent totaled approximately RMB4.54 billion, a year-on-year increase of approximately 31.4%. The Group’s liquidity remained strong, with cash and bank balances classified as current assets of approximately RMB12.18 billion, bank deposits classified as non-current assets of approximately RMB10.25 billion, wealth management products of approximately RMB10.56 billion in total, and total fund reserves of approximately RMB32.99 billion for the Year.The Board of Directors has recommended a final dividend payment of HK5 cents per share (2024: HK4 cents). Together with an interim dividend of HK5 cents already paid, the total dividend for the year amounts to HK10 cents (2024: HK7 cents).Sales: Innovation-driven growth fuels sustained sales momentumDuring the Year, the Group consistently increased investments to enhance R&D quality and efficiency, which led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. Sales of innovative products increased by 26.2% year-on-year to approximately RMB15.22 billion, accounting for approximately 47.8% of the Group’s revenue. If the sales is categorized by therapy field, sales of oncology drugs increased by 22.8% year-on-year to approximately RMB13.18 billion, accounting for approximately 41.4% of the Group's revenue. Sales of surgical/analgesic medications increased by 12.8% year-on-year to approximately RMB5.03 billion, accounting for approximately 15.8% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. Focus V(R) (Anlotinib Hydrochloride Capsules) has been approved for 10 indications, and several new indications are currently in the marketing application or Phase III clinical trial stage. Its combination therapy has demonstrated superior efficacy in the treatment of lung cancer. From 2023 to 2025, the Group obtained approval for and launched a total of 7 national category 1 innovative oncology drugs and 4 oncology biosimilars. The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.In the field of surgery/analgesia, Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) have ranked first in market share of topical analgesia for many years. The second-generation flurbiprofen patch is anticipated to receive marketing approval within the year and is expected to strengthen its market leadership through this dosage form upgrade. Meanwhile, Putanning(R) (Meloxicam Injection (II)), China’s first once-daily long-acting analgesic NSAIDs injection, was approved for marketing by the NMPA and the FDA in May 2025 and has been included in the NRDL in 2025. It is expected to become another blockbuster product for the Group in pain management area.R&D: Technology-driven advancements significantly enhance R&D quality and efficiency R&D innovation has always been the key driving force of the Group. The Group has established multiple R&D centers in places including Shanghai, Nanjing, Beijing, and Guangzhou, and has successfully built diversified innovative technology platforms covering such fields as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches. For the year ended 31 December 2025, the Group’s total R&D investment amounted to approximately RMB 6.32 billion, accounting for approximately 19.8% of Group revenue.The Group also attaches tremendous importance to the protection of intellectual property rights and actively files patent applications to enhance its core competitiveness. During the Year, the Group filed 1,167 new patent applications and received 273 patent grants. As at the end of the Year, the Group had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.Prospects: Focusing on innovation and firmly promoting internationalization strategyLooking ahead, the Group will continue to focus on innovation and remain deeply committed to four core therapeutic areas – oncology, liver / cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. It will leverage AI to deeply empower the entire R&D process and continuously strengthen its R&D and innovation capabilities to drive steady business growth. Over the next three years (2026-2028), the Group’s innovation pipeline is expected to experience another wave of explosive growth, with nearly 20 national category 1 innovative drugs expected to be approved for marketing, including multiple blockbuster products with first-in-class (FIC) and best-in-class (BIC) potential. It is expected that by the end of 2028, the total number of innovative products launched by the Group will be around 40, positioning them as the core driver of business growth.At the same time, the Group will firmly advance its internationalization strategy. In February 2026, the Group announced that it had granted Sanofi an exclusive worldwide license to develop, manufacture, and commercialize Rovadicitinib, with the right to receive payments of up to US$1.53 billion, plus tiered royalties of up to double digits based on annual net sales of Rovadicitinib. Going forward, out-licensing will become another important source of revenue for the Group, continuously injecting strong, new momentum into its performance growth and formally launching a second growth curve supported by revenue from internationalization. In addition, the Group remains committed to adhering to the "win-win cooperation" philosophy and is dedicated to building an open and diverse innovation ecosystem. Through in-depth cooperation with the world's leading pharmaceutical companies, biotechnology firms and scientific research institutions, the Group is accelerating the aggregation of high-quality global resources, promoting the co-creation and sharing of innovative outcomes, and continuously strengthening its market leadership. Through the integration of high-quality resources such as LaNova Medicines and Hygieia, the Group has significantly strengthened its R&D capabilities in cutting-edge fields, including tumor immunology and siRNA.Looking ahead, the Group will continue to drive innovation through its dual engines of internal R&D and strategic cooperation, accelerate its development through internationalization, and make steady progress towards its strategic goal of becoming a world-class innovative pharmaceutical company.For detailed information on the Group’s results for the Year, please refer to the official announcements uploaded by the Group to the Hong Kong Stock Exchange website and its official website.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative R&D-driven pharmaceutical group in China. Its business covers the entire industrial chain, including R&D platforms, intelligent manufacturing, and a robust sales system. Its products encompass a wide range of biologics and chemical drugs, with a strong presence in four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. The company was listed on the Hong Kong Stock Exchange in 2000, was included as a constituent of the MSCI China Index in 2013, became a constituent of the Hang Seng Index in 2018, and was added to the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company has been named among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine Pharm Exec for seven consecutive years, and has been recognized as one of the "Top 50 Best Companies in Asia" by Forbes Asia for three consecutive years.For more information, please visit: www.sbpgroup.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重點成果- 年內，集團共有4個創新產品獲NMPA批准上市，分別為賽坦欣(R)（庫莫西利膠囊）、聖赫途(R)（宗艾替尼片）、普坦寧(R)（美洛昔康注射液(II)）和安啟新(R)（注射用重組人凝血因子VIIa N01）。- 2025年，集團創新產品收入達到人民幣152.2億元，同比增長26.2%。此外，集團已在上海、南京、北京、廣州等地建立多個研發中心，並成功構建了涵蓋小分子、蛋白降解劑、siRNA、單抗／雙抗、抗體偶聯藥物（ADC）、吸入製劑、透皮貼劑等領域的多元化創新技術平台。- 截至2025年12月31日，集團共有39個腫瘤領域、10個肝病╱心血管代謝領域、14個呼吸╱自免領域、和6個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中，1個腫瘤領域、2個外科╱鎮痛領域產品處在上市申請階段；13個腫瘤領域、1個肝病╱心血管代謝領域、5個呼吸╱自免領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期，9個腫瘤領域、6個肝病╱心血管代謝領域、5個呼吸╱自免領域、2個外科╱鎮痛領域的創新候選藥物處於臨床II期，另有16個腫瘤領域、3個肝病╱心血管代謝領域、4個呼吸╱自免領域、1個外科╱鎮痛領域的創新候選藥物處於臨床I期。- 福可維(R)（鹽酸安羅替尼膠囊）是一款新型小分子多靶點酪氨酸激酶抑制劑，目前已獲批10項適應症，其一線非鱗狀非小細胞肺癌、一線胰腺癌等多項新適應症正在開展III期臨床研究，預計未來兩年將逐步遞交上市申請。- 2023-2025年，集團共有7款腫瘤領域的國家1類創新藥獲批上市，分別為：賽坦欣(R)（庫莫西利膠囊）、聖赫途(R)（宗艾替尼片）、億立舒(R)（艾貝格司亭α注射液）、安得衛(R)（貝莫蘇拜單抗注射液）、安柏尼(R)（富馬酸安奈克替尼膠囊）、安洛晴(R)（枸櫞酸依奉阿克膠囊）和安方寧(R)（格索雷塞片）；以及4款腫瘤領域的生物類似藥獲批上市，分別為：安倍斯(R)（貝伐珠單抗注射液）、得利妥(R)（利妥昔單抗注射液）、賽妥(R)（注射用曲妥珠單抗）和帕樂坦(R)（帕妥珠單抗注射液）。該等產品在2025年快速放量，成為集團收入增長的重要貢獻品種。- 天晴甘美(R)（異甘草酸鎂注射液）是第四代甘草酸製劑，目前已獲批3個適應症。集團年內著力加強學術推廣，透過各層級的學術會議增強了醫生覆蓋和專家認可，同時大力發掘新患者拓展新市場，並積極推進回顧性研究，為其臨床使用提供更多的學術證據。- TQC3721（PDE3／4抑制劑）是一款PDE3／4雙重抑制劑，目前正在中國開展III期臨床試驗，用於治療中重度慢性阻塞性肺病（COPD）。集團正在開發TQC3721的多種劑型：吸入用混懸液位於III期臨床階段，吸入粉霧劑位於II期臨床階段，有望透過多種劑型進一步提升患者的依從性。 - 澤普思(R)／得百安(R)（氟比洛芬凝膠貼膏）是中國首個獲批上市的國產凝膠貼膏，連續多年蟬聯外用鎮痛市場份額第一位。集團聚焦高潛力地區開發，深入拓展市場覆蓋，並逐步擴大產能以滿足市場的旺盛需求，推動澤普思／得百安銷售額持續快速增長。集團開發的第二代氟比洛芬貼劑預計將在年內獲批上市，透過劑型升級，二代產品可顯著提高藥物透皮吸收度，增強貼膏粘附性，從而提升患者的依從性。 香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 中國領先的創新研發驅動型醫藥集團-中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2025年12月31日止12個月（「年內」）之經審核財務業績。年內，集團收入增長約10.3%至約318.3億元（人民幣，下同）。來自持續經營業務之歸屬於母持有者盈利（財務報表所示）約23.4億元，按年增長約22.0%。來自持續經營業務之歸屬於母公司持有者盈利計算之每股基本盈利約人民幣13.02分，較去年增加約24.0%。歸屬於母公司持有者之基本溢利約45.4億元，按年增長約31.4%。集團流動資金保持充裕，年內有計入流動資產之現金及銀行結餘約121.8億元、計入非流動資產之銀行存款約102.5億元，理財管理產品總額約105.6億元，資金儲備總額約329.9億元。董事會建議派發末期股息每股5港仙（2024年：4港仙），連同已派發中期股息每股5港仙，全年合共派發股息每股10港仙（2024年：7港仙）。銷售：創新引領，銷售動能持續釋放年內，集團持續加大投入以提升研發質效，研發實力顯著增強，驅動銷售收入持續增長，成果豐碩。年內，創新產品之收入同比增加26.2%，達約152.2億元。至於分治療領域，抗腫瘤用藥之收入同比增加22.8%，達約131.8億元，佔集團收入約41.4%。外科／鎮痛用藥之收入同比增加12.8%，達約50.3億元，佔集團收入約15.8%。腫瘤領域，集團全面佈局非小細胞肺癌領域，覆蓋多種分型的全線治療，福可維(R)（鹽酸安羅替尼膠囊）已獲批10項適應症，多項新適應症處於上市申請或III期臨床階段，其聯合療法在肺癌治療中展現出優效。2023年至2025年間，集團共有7款腫瘤領域的國家1類創新藥以及4款腫瘤領域的生物類似藥獲批上市，該等產品在2025年快速放量，成為集團收入增長的重要貢獻品種。於外科╱鎮痛領域，澤普思(R)／得百安(R)（氟比洛芬凝膠貼膏）連續多年蟬聯外用鎮痛市場份額第一位，第二代氟比洛芬貼劑預計將在年內獲批上市，有望透過劑型升級鞏固市場領先地位。同時，中國首款一日一次長效鎮痛NSAIDs注射液普坦寧(R)（美洛昔康注射液（II））已於2025年5月獲得NMPA和FDA的上市批准，並已被新增納入2025年國家醫保藥品目錄，有望成為集團鎮痛領域的又一款重磅產品。研發：技術築基，研發質效顯著提升研發創新始終是集團的核心驅動力，集團目前已在上海、南京、北京、廣州等地建立多個研發中心，並成功構建了涵蓋小分子、蛋白降解劑、siRNA、單抗／雙抗、抗體偶聯藥物（ADC）、吸入製劑、透皮貼劑等領域的多元化創新技術平台。截至二零二五年十二月三十一日止年度，研發總投入約人民幣63.2億元，佔集團收入約19.8%。集團亦重視保護知識產權，積極申報各項專利，以提高核心競爭力。年內，集團提交專利申請1,167項、獲得專利授權273項。截至年末，集團累計有效專利申請達5,724項，累計有效專利授權達2,120項。展望：聚焦創新，堅定推進國際化戰略展望未來，集團將繼續聚焦創新，深耕腫瘤、肝病／心血管代謝、呼吸／自免、外科／鎮痛四大核心治療領域，以AI深度賦能研發全流程，持續強化創新研發能力推動業績穩步增長。預計未來三年（2026-2028年），集團創新管線將迎來新一輪爆發式增長，預計近20款國家1類創新藥有望獲批上市，涵蓋多款具備全球同類首創 (FIC) ／同類最佳 (BIC) 潛力的重磅產品。預計至2028年底，集團上市創新產品總數將達到近40款，成為驅動業績增長的核心引擎。同時，集團堅定推進國際化戰略。2026年2月，集團宣佈授予Sanofi在全球範圍內開發、生產及商業化羅伐昔替尼的獨家許可，並有權獲得最高15.3億美元的付款，以及基於羅伐昔替尼年度淨銷售額的高達雙位數的銷售提成。未來，對外授權合作將成為集團的又一重要收入來源，持續為業績增長注入強勁新動能，正式開啟以國際化收入為支撐的第二增長曲線。此外，集團始終秉持「合作共贏」理念，著力構建開放多元的創新生態體系。透過與全球頂尖藥企、生物科技公司及科研機構的深度合作，集團正加速彙聚全球優質資源，推動創新成果的共創共享，持續鞏固市場領導地位。透過整合禮新醫藥、赫吉亞等優質資源，集團在腫瘤免疫及siRNA等前沿賽道的研發實力顯著增強。未來，集團將繼續以自主研發與戰略合作雙引擎驅動創新，以國際化加速發展，向世界級創新醫藥企業的戰略目標穩步邁進。有關集團本年度詳細業績資料，請參閱集團上載至香港聯合交易所及官網之正式公告。有關中國生物製藥有限公司（股票編號：1177）中國生物製藥，連同其附屬公司，是中國領先的創新研究和研發驅動型醫藥集團，業務覆蓋醫藥研發平台、智慧化生產和強大銷售體系全產業鏈。產品包括多種生物藥和化學藥，在腫瘤、肝病／心血管代謝、呼吸／自免、外科／鎮痛四大治療領域處於優勢地位。公司於2000年在香港聯交所上市，2013年入選MSCI全球標準指數之中國指數成分股；2018年入選恒生指數成分股；2020年入選恒生滬深港通生物科技50指數成分股、恒生中國(香港上市)25指數。中國生物製藥連續七年榮登美國權威雜誌《製藥經理人》發佈的「全球製藥企業TOP50」，連續三年獲評《福布斯》(亞洲) 「亞太最佳公司50強」。有關中國生物製藥的進一步資料，請瀏覽: www.sbpgroup.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the GameU.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. modelsThe polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for which it was named. From its earliest days, the polo shirt was designed with purpose, worn by players seeking performance on the polo fields. Today, U.S. Polo Assn. celebrates this timeless favorite, not just as a fashion item, but as an icon born from sport and carried forward through generations of players and consumers all over the world.The polo shirt is one of the most iconic essentials dating back over 100 years, notable for its unique fusion of sport and style. Originally designed with breathable pique knit, a soft collar, and lightweight construction to meet the demands of competitive sports, it has evolved into a timeless essential, suitable for casual elegance and leisurewear.The polo shirt traces its origins to polo players, where it was created out of necessity for the sport. Polo players modified long‑sleeved cotton shirts to better handle heat, movement, and wind while playing. These functional, sport‑driven adaptations represent the earliest form of what would become the polo shirt. In the early 20th century, polo players helped formalize these functional elements as the sport gained popularity, reinforcing the shirt's connection to the sport and its functional design.Over the years, the polo shirt became a cornerstone of casual sportswear around the world, symbolizing preppy style, luxury leisure culture, and contemporary athleisure, seamlessly transitioning from polo fields to college campuses and boardrooms. Its enduring adaptability is demonstrated by distinct reinventions across the decades; the ability to evolve has ensured the polo shirt's lasting relevance and cultural significance.As the official sports brand of the USPA, founded in 1890 and one of the oldest sports governing bodies in the United States, U.S. Polo Assn. occupies an authentic place in the history of the polo shirt."The polo shirt's DNA is deeply rooted in the inspirational sport that inspired it," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar, global U.S. Polo Assn. brand. "With An Icon Born from the Game, we're honoring a legacy that began on the field and continues to shape how polo players, sports fans, and consumers all over the world live, move, and express themselves today, and for future generations."An Icon Born from the Game reinforces that legacy by connecting the polo shirt's origins in the sport, while celebrating its place in modern culture."The polo shirt was designed for the game with a real purpose on the field, but it's also what I wear off the field to go out to dinner or hang out with friends and family," said Nico Escobar, U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player. "I love that U.S. Polo Assn. understands both the performance aspect and how the polo shirt fits into everyday life.""U.S. Polo Assn.'s authentic connection to the sport and the way it supports the game of polo around the world is why I wear it - both on the field and off," adds Escobar.Global Launch: An Icon Born from the GameLaunching globally across 190 countries in Spring 2026, An Icon Born from the Game will come to life through a coordinated, multi‑channel presence designed to make the U.S. Polo Assn. polo shirt unmistakably visible wherever consumers engage with the sport-inspired brand. In stores, dedicated polo shirt focus areas, including the brand's iconic polo walls, window displays, and visual merchandising moments, will highlight the full range of styles through bold color stories, clear categorization, and campaign signage anchored by the slogan.Across outdoor and print advertising, hero imagery shot on location brings the polo shirt back to the field, reinforcing its authentic connection to the sport, while digital and social media activations extend the story through short‑form content and global storytelling. Together, these touchpoints create a consistent, immersive expression of the polo shirt as a true icon rooted in sport but relevant to everyday life.Further, An Icon Born from the Game is launching around two of the sport's most important events in the United States - the prestigious USPA Gold Cup® and one of the most competitive tournaments in the world, the U.S. Open Polo Championship®, which concludes with the Championship Final on April 26."An Icon Born from the Game is about owning our truth and telling it boldly on a global scale," said Stefanie Coroalles, Vice President, Global Brand Marketing. "The Global Polo Shirt Campaign brings together heritage, product, and self-expression, showing how the polo shirt moves effortlessly from sport to everyday life.""This launch is a proud moment for us, one that brings our heritage to life in a way that feels modern, visible, and unmistakably U.S. Polo Assn.," adds Coroalles.Product Pillars: Play It Your Way"Every U.S. Polo Assn. polo shirt is designed with intention by balancing style, comfort, function, and authentic sport details," said Brian Kaminer, Senior Vice President, Brand and Product Development. "From heritage-inspired construction to modern performance fabrics, our U.S. Polo Assn. collections reflect how the polo shirt continues to evolve while staying true to its sports roots."The global polo shirt campaign showcases the versatility of the icon through five distinct expressions that give the consumer the opportunity to "Play It Your Way" when styling with the polo shirt.Play It Sporty is the polo shirt that carries the legacy of U.S. Polo Assn. in every stitch. Featuring authentic detailing, iconic branding, and sport-inspired elements, this timeless silhouette connects directly to the game that started it all. Official crests, classic cuts, and traditional design details celebrate the sport of polo's history and the brand's deep-rooted heritage.Play It Classic is the polo shirt for the moments that make up everyday life. Clean, comfortable, and easy to style, it's the go-to option when you want something that always works. Designed to be worn again and again, it fits seamlessly into any routine, whether casual, relaxed, or slightly dressed up.Play It in Motion with the performance polo shirt engineered for action. Advanced technical fabrics deliver moisture-wicking comfort, breathability, and stretch that moves with you throughout the day. Designed for polo players on the field or in life in motion, it balances durability and function with a sharp, modern look.Play It Bold is the fashion polo shirt built for self-expression. Defined by confidence and style, this version brings personality and freedom to a familiar icon. Worn casually or styled with intention, it shows how versatile the polo shirt can be when it's shaped by confidence and worn on an individual's own terms.Play It Elevated is the premium polo shirt made for moments that call for refinement. Crafted with elevated materials and thoughtful detailing, it offers a polished look without feeling formal. Clean lines and a thoughtful fit create a composed yet confident style that balances ease with sophistication.U.S. Polo Assn.'s seasonal polo shirts are offered across men's, women's, and kids' collections in an expansive range of fabrics, finishes, and colors - from classic neutrals to vibrant hues. Updated designs feature textured ribs, subtle patterns, and elevated construction details, finished with the brand's signature Double Horsemen logo - a mark of authenticity and a symbol of the sport.U.S. Polo Assn. continues to incorporate products aligned with its global sustainability program, USPA Life, reflecting the brand's commitment to responsible sourcing and long-term environmental initiatives. The USPA Life Polo Shirt, arriving in stores Spring 2027, builds on U.S. Polo Assn.'s most iconic style, designed with thoughtfully chosen, preferred materials that reflect the brand's commitment to improving the global footprint of this iconic staple. From 100% preferred cotton fabric to the finishing details like buttons and thread, each element has been selected to reduce impact while preserving the classic look, comfort, and quality customers expect from a U.S. Polo Assn. polo shirt.U.S. Polo Assn. apparel and accessories are available in U.S. Polo Assn. stores and online at uspoloassnglobal.com.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sports content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +954.673.1331 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR and Comms SpecialistPhone +561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州西棕櫚灘, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 由1890年成立的美國馬球協會（USPA）所授權的官方運動品牌 U.S. Polo Assn.，今日宣布推出全球馬球衫宣傳活動「源自賽場的經典」。這項全球性活動旨在向標誌性的馬球衫致敬，彰顯其純正的運動淵源，以及它如何演變為全球最歷久彌新的時尚經典之一。U.S. Polo Assn. 全球品牌大使、6級美國職業馬球選手尼科·埃斯科巴（Nico Escobar）身著馬球白裝與經典海軍藍 U.S. Polo Assn. 馬球衫，騎乘愛駒觀賽，展現「源自賽場的經典」精神U.S. Polo Assn. 模特兒身著馬球衫，於南卡羅來納州查爾斯頓參與 2026 春夏全球系列攝影「馬球衫：源自賽場的經典」宣傳影像，由 U.S. Polo Assn. 模特兒演繹Polo衫的起源可追溯至馬球場，其設計深受運動動作、競技精神以及這項賦予其名稱的運動所塑造。自問世之初，Polo衫便以實用為本，由追求賽場表現的球員們所穿著。時至今日，U.S. Polo Assn. 不僅將這款歷久不衰的經典視為時尚單品，更視其為源自運動、並由全球數代球員與消費者共同傳承的標誌性象徵。馬球衫是擁有逾百年歷史的最具代表性經典單品之一，以其獨特的運動與時尚融合而著稱。最初採用透氣的平紋針織面料、柔軟的領口及輕量結構，以滿足競技運動的需求；如今已演變為永恆的經典單品，既適合展現休閒優雅，亦是理想的生活休閒服飾。Polo衫的起源可追溯至馬球運動員，其誕生源於這項運動的實際需求。馬球運動員為在比賽中更好地應對高溫、動作與風勢，對長袖棉質襯衫進行了改良。這些以功能性為導向的運動改裝，正是日後Polo衫的雛形。20世紀初，隨著馬球運動日益普及，運動員們協助將這些功能性元素正式化，進一步鞏固了Polo衫與這項運動及其功能性設計之間的連結。多年來，馬球衫已成為全球休閒運動服飾的基石，象徵著學院風、奢華休閒文化與當代運動休閒風，從馬球場到大學校園，再到會議室，皆能無縫融入。數十年來，馬球衫歷經多次獨特的革新，展現出其持久的適應性；這種不斷演進的能力，確保了馬球衫歷久不衰的流行地位與文化意義。作為美國馬球協會（USPA）的官方運動品牌，U.S. Polo Assn. 佔據了馬球衫歷史中獨一無二的地位。USPA 成立於 1890 年，是美國歷史最悠久的體育管理機構之一。「馬球衫的基因深深植根於那項啟發它的鼓舞人心運動，」USPA Global 總裁兼執行長 J. Michael Prince 表示。該公司負責管理並推廣這個價值數十億美元的全球性 U.S. Polo Assn. 品牌。「透過『源自賽場的傳奇』系列，我們致敬這份始於球場的傳承，它持續塑造著全球馬球選手、運動迷及消費者當下的生活、行動與自我表達方式，並將影響未來的世代。」「源自賽場的傳奇」系列透過連結馬球衫與這項運動的淵源，同時彰顯其在現代文化中的地位，進而鞏固這份傳承。「這件馬球衫是專為比賽設計，在球場上確實有其實際用途，但它也是我場下外出用餐或與親友聚會時會穿的服裝，」U.S. Polo Assn. 全球品牌大使、6級美國職業馬球選手尼科·埃斯科巴（Nico Escobar）表示。「我很欣賞 U.S. Polo Assn. 既重視機能表現，也懂得如何讓馬球衫融入日常生活。」「U.S. Polo Assn. 與這項運動的真摯連結，以及它對全球馬球運動的支持，正是我無論在場上或場下都選擇穿著它的原因，」埃斯科巴補充道。全球發佈：「源自賽場的經典」「源自賽場的經典」系列將於2026年春季在全球190個國家同步上市，透過協調一致的多渠道佈局，讓美國馬球協會的馬球衫在消費者接觸這個運動靈感品牌的任何場合都清晰可見。在實體店鋪中，專門的馬球衫展示區——包括品牌標誌性的馬球衫牆、櫥窗陳列及視覺 merchandising 亮點——將透過大膽的色彩故事、清晰的品類劃分，以及以標語為核心的活動標識，全面呈現各類款式。無論是戶外廣告還是平面廣告，現場拍攝的主視覺影像將馬球衫帶回球場，強化其與這項運動的真實連結；而數位與社群媒體的推廣活動，則透過短片內容與全球敘事延展這個故事。這些接觸點共同營造出連貫且沉浸式的呈現，彰顯馬球衫作為真正標誌性單品的特質——它植根於運動，卻也與日常生活息息相關。此外，「源自賽場的經典」活動將配合美國兩項最重要的馬球賽事同步推出——包括享有盛譽的 USPA 金盃®（USPA Gold Cup®），以及全球競爭最激烈的賽事之一「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），該賽事將於 4 月 26 日舉行冠軍決賽。「『源自賽場的經典』旨在擁抱我們的真實本質，並在國際舞台上大膽傳遞這份精神，」全球品牌行銷副總裁史蒂芬妮·科羅亞萊斯（Stefanie Coroalles）表示。「這場全球馬球衫宣傳活動融合了品牌傳承、產品特色與自我表達，展現了馬球衫如何從運動場域無縫融入日常生活。」「此次發布對我們而言是值得驕傲的時刻，它以現代、鮮明且無可辯駁的 U.S. Polo Assn. 風格，將我們的傳承賦予新生，」科羅亞萊斯補充道。產品核心理念：隨心所欲，盡情展現「每一件 U.S. Polo Assn. 馬球衫皆經過精心設計，在風格、舒適度、功能性與純正運動細節之間取得完美平衡，」品牌與產品開發資深副總裁布萊恩·卡米納（Brian Kaminer）表示。「從汲取傳統靈感的剪裁到現代機能面料，我們的 U.S. Polo Assn. 系列展現了馬球衫如何在忠於運動本源的同時，持續演進。」這場全球馬球衫宣傳活動透過五種獨特風格，展現這款經典單品的百變魅力，讓消費者在搭配馬球衫時，能盡情「隨心所欲，盡情展現」。「運動風」系列（Play It Sporty）的每一針每一線都承載著 U.S. Polo Assn. 的傳承。憑藉純正的細節、標誌性的品牌標識以及受運動啟發的元素，這款永恆的剪裁直接連結了品牌起源的馬球運動。官方徽章、經典剪裁與傳統設計細節，共同致敬馬球運動的歷史與品牌深厚的傳承。「Play It Classic」系列專為日常生活的點滴時刻而生。簡約、舒適且易於搭配，是您尋求百搭之選時的首選。這款專為反覆穿著而設計的 polo 衫，無論是休閒、放鬆或稍作打扮的場合，都能完美融入您的日常。「Play It in Motion」系列，專為動態活動打造的高性能POLO衫。採用先進技術面料，具備吸濕排汗的舒適感、透氣性及彈性，全天候隨您的動作靈活伸展。無論是球場上的POLO球員，還是追求動態生活的您，這款設計皆能兼顧耐用性與功能性，同時展現俐落現代的風格。「Play It Bold」系列，是專為自我表達而生的時尚POLO衫。這款作品以自信與風格為核心，為這款經典單品注入個性與自由。無論是隨性穿著或精心搭配，它都展現了當Polo衫由自信塑造、並依個人風格穿出時，其多變的魅力。「Play It Elevated」是為講究精緻的時刻打造的頂級Polo衫。採用高級面料與細膩工藝，呈現出精緻外觀卻不顯拘謹。簡潔的線條與貼合的剪裁，營造出沉穩而自信的風格，完美平衡了舒適與優雅。U.S. Polo Assn. 的季節性馬球衫涵蓋男裝、女裝及童裝系列，提供豐富多樣的面料、質感與色彩選擇——從經典中性色到鮮豔色調一應俱全。全新設計採用立體羅紋、低調圖案及精緻的工藝細節，並飾以品牌標誌性的「雙騎士」標誌——這不僅是正品的保證，更是這項運動的象徵。U.S. Polo Assn. 持續推出符合其全球永續發展計畫「USPA Life」的產品，體現品牌對負責任採購及長期環保倡議的承諾。將於 2027 年春季上市的 USPA Life 馬球衫，以 U.S. Polo Assn. 最具標誌性的款式為基礎，採用經過深思熟慮挑選的優質面料，彰顯品牌致力於改善這款經典單品對全球環境影響的決心。從 100% 優質棉面料到鈕扣與縫線等細節處理，每個環節皆經過精心挑選，在降低環境影響的同時，仍完整保留顧客對 U.S. Polo Assn. 馬球衫所期待的經典外觀、舒適度與品質。U.S. Polo Assn. 的服飾與配件現已於 U.S. Polo Assn. 實體門市及官網 uspoloassnglobal.com 販售。關於 U.S. Polo Assn. 與 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方運動品牌。USPA 成立於 1890 年，是美國規模最大的馬球俱樂部與馬球選手組織。憑藉數十億美元的全球業務規模，以及透過超過 1,200 家 U.S. Polo Assn. 零售店和數千個其他銷售據點的全球分銷網絡，U.S. Polo Assn. 在全球 190 多個國家為男女及兒童提供服飾、配件和鞋類產品。該品牌贊助全球各大馬球賽事，包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport 以及印度 Star Sports 簽訂的歷史性合作協議，由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播，讓全球數百萬體育迷首次得以欣賞這項令人熱血沸騰的運動。根據《License Global》的報導，U.S. Polo Assn. 一直與 NFL、PGA 巡迴賽及一級方程式賽車並列為全球頂尖的運動授權商之一。此外，這個以運動為靈感的品牌更因全球業務成長及運動內容而獲得國際獎項肯定。憑藉其作為全球品牌的巨大成功，U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導，並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會（USPA）的子公司，負責管理市值數十億美元的運動品牌 U.S. Polo Assn.。USPA Global 同時管理其子公司 Global Polo，該公司是全球馬球運動內容的領導者。欲了解更多資訊，請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。如需更多資訊，請聯絡：Stacey Kovalsky - 全球公關與傳播副總裁電話 +954.673.1331 - 電子郵件：skovalsky@uspagl.com  凱拉·德雷克（Kaela Drake） - 資深公關與傳播專員電話 +561.530.5300 - 電子郵件：kdrake@uspagl.com 消息來源：U.S. Polo Assn. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com